Pyranose Biotherapeutics

PBI develops 'Biobetter' protein therapeutics from highly successful drugs that are at the end of their intellectual property life.

  • Stage Concept Only
  • Industry Biotechnology
  • Location San Carlos, CA, USA
  • Currency USD
  • Founded November 2010
  • Employees 2

Company Summary

PBI idevelops minimally invasive means to modify existing protein therapeutics, which are in the public domain, to improve their efficacy and to facilitate manufacture, providing lower production costs and lower costs to patients.

Team

  • Thomas Warner
    Founder, CSO

    Over 25 years of experience in the biotechnology industry He is well known for his work in host cell metabolic engineering and glycosylation issues.He was senior scientist in the protein analytics group at Genentech for 10 years. He holds several patents on the optimization of protein production.

    He has also served a leadership role at Immunetech, inc and Intrexon ,inc as Director of Analytical Development and Senior Research Fellow.

  • John Patton
    CEO (acting)

    Dr. Patton is an experienced entrepreneur having founded several successful companies in the San Francisco Bay area, including Nektar Pharmaceuticals and Dance Pharmaceuticals.. John brings a wealth of business acumen and scientific judgement to PBI.

  • David Pyrce
    Advisor Business Development

    Twenty-five plus years of domestic and international entrepreneurial experience including operating experience in the biotechnology and pharmaceteucal industry

  • Richard Waldron
    Advisor Finance

    CFO finance manager, human resources, IR, IT and intellectual property functions. Mr Waldron has completed over 45 corporate finance transactions including financing and mergers and acquisitions.

  • Thomas Warner

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free